Day One Biopharmaceuticals, Inc.
DAWNNASDAQHealthcare
$21.53
+$0.00(+0.00%)
Market Cap$2.2B
P/E Ratio—
52W High$21.53
52W Low$5.635
Day One Biopharmaceuticals, Inc. (DAWN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DAWN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.16B | $0.13B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.02B | $0.01B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.14B | $0.13B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | 89.12% | 95.98% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.15B | $0.23B | $0.13B | $0.09B | $0.04B |
| G&A Expenses | $0.00B | $0.00B | $0.08B | $0.06B | $0.03B |
| Total Operating Expenses | $0.27B | $0.34B | $0.21B | $0.15B | $0.07B |
| Operating Income | ($0.13B) | ($0.22B) | ($0.21B) | ($0.15B) | ($0.07B) |
| Operating Margin %(computed) | -80.76% | -165.65% | — | — | — |
| Interest Income | $0.02B | $0.02B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.11B) | ($0.09B) | ($0.19B) | ($0.14B) | ($0.07B) |
| Income Tax Expense | ($0.00B) | $0.01B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.11B) | ($0.10B) | ($0.19B) | ($0.14B) | ($0.07B) |
| Net Margin %(computed) | -67.85% | -72.81% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.04 | $-1.02 | $-2.37 | $-2.02 | $-1.14 |
| Wtd Avg Shares | 0.10B | 0.09B | 0.08B | 0.07B | 0.06B |
| EBITDA | ($0.12B) | ($0.22B) | ($0.21B) | ($0.15B) | ($0.07B) |
| EBITDA Margin %(computed) | -78.37% | -164.10% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Day One Biopharmaceuticals, Inc. data
About Day One Biopharmaceuticals, Inc. (DAWN) Income Statement
Day One Biopharmaceuticals, Inc. (DAWN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, DAWN reported revenue of $0.16B, gross profit of $0.14B (gross margin 89.12%), and net income of ($0.11B) — a net profit margin of -67.85%.
Frequently asked questions
DAWN · 4 questionsDay One Biopharmaceuticals, Inc. (DAWN) reported revenue of $0.16B for 2025, up 20.6% year-over-year.
DAWN revenueDAWN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08